PTC Therapeutics agrees to buy Sangamo’s ST-920 Fabry gene therapy assets for $111 million upfront

Reuters2026/08/28 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PTC Therapeutics entered an asset purchase agreement to buy Sangamo’s ST-920 gene therapy program for Fabry disease.
Deal terms include an upfront payment of $111 million, with up to $100 million tied to FDA accelerated approval and full approval milestones.
Closing hinges on Delaware bankruptcy court authorization, Hart-Scott-Rodino clearance, and other customary conditions.
A bankruptcy court hearing on the transaction is scheduled for Sept. 10, 2026, with an outside closing date of Oct. 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001070081-26-000019), on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PTC Therapeutics agrees to buy Sangamo’s ST-920 Fabry gene therapy assets for $111 million upfront

You may also like

Crypto prices